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Nonsteroidal Antiinf lammatory Drugs 
and Colorectal Cancer 
Joshua E. Muscat, M.P.H., Steven D. Stellman, Ph.D., M.P.H., 
and Ernst L. Wynder, M.D. 
Background. The association between the use of non- 
steroidal antiinflammatory drugs (NSAID) and large 
bowel cancer was examined in a hospital-based case- 
control study of 511 patients with colorectal cancer and 
500 age-sex matched control subjects. 
Methods. Regular NSAID use was defined as at  least 
3 times per week for 1 or more years before the date of 
hospital admission. Odds ratios (OR) were calculated by 
the duration of NSAID use and according to the medical 
reasons given for taking NSAIDs. 
Results. The prevalences of regular NSAID use were 
15% for male patients, 8% for female patients, and 20% 
for control subjects. Overall, NSAID use was associated 
with a statistically significant risk reduction in men (OR 
= 0.64; 95% confidence interval [CI], 0.42-0.97) and in 
women (OR = 0.32; 95% CI, 0.18-0.57). The estimate de- 
creased with duration among men but increased with du- 
ration among women. The risk reduction among patients 
who took NSAIDs to prevent heart disease was 0.67 (95% 
CI, 0.38-1.13) for men and 0.43 (95% CI, 0.12-1.59) for 
women. For treating headache pain, the OR was 0.5 (95% 
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CI, 0.23-1.09) for men and 0.64 (95% CI, 0.25-1.62) for 
women. The use of NSAID was not found to be associated 
with the stage of cancer at diagnosis. The OR for daily 
acetaminophen use was 1.07 (95% CI, 0.35-3.23) for men 
and 0.59 (95% CI, 0.27-1.25) for women. 
Conclusions. The regular use of NSAIDs was associ- 
ated with an overall significant risk reduction of colorec- 
tal cancer in men and in women. Among female patients, 
the greater protective effect associated with short term 
NSAID use compared with long term NSAID use may re- 
flect a sampling bias. Cancer 1994; 74:1847-54. 
Key words: aspirin, acetaminophen, colon, rectum, pros- 
taglandins. 
Nonsteroidal antiinflammatory drugs (NSAIDs) are 
chemopreventive agents in experimentally-induced co- 
lon cancer models.'-'3 A possible mechanism for this 
action is the inhibition of select pathways of prostaglan- 
din synthesis. Certain prostaglandins have been shown 
to increase cell proliferation and tumor g r o ~ t h , ' ~ , ' ~  and 
affect immune response.16 Another type of analgesic, 
acetaminophen, also has been suggested to be a prosta- 
glandin synthesis inhibitor, although the mechanism of 
its action is poorly ~nderstood.'~ 
The relationship between NSAIDs and colorectal 
cancer have been studied in several human populations 
(Table 1). Regular intake of NSAIDs reduced the risk or 
mortality from colon or colorectal cancer in some epide- 
miologic studies,'8-22 although one prospective study 
did not support such an ass~ciat ion.~~ No effect of aspi- 
rin was observed in a randomized clinical trial of low 
dose aspirin use after 5 years of follow-up.24 However, 
regular aspirin use reduced the occurrence of adenomas 
in a case-control studyZ5 and in a separate clinical trial 
of patients who had a resection of a large bowel ade- 
noma after 1 year of 
Despite these fairly consistent findings, it has not 
been shown that long term users of NSAIDs have a 
lower risk of colon cancer than short term users. In ad- 
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with NSAID intake in some studies may have reflected 
the lifestyle or health behaviors of the NSAID users 
rather than the medication itself. The current case-con- 
trol study examines regular NSAID and acetaminophen 
intake among newly diagnosed subjects according to 
the frequency, duration, and medical reasons given for 
their usage. 
Methods 
A case-control study of large bowel cancer was de- 
signed specifically to assess the effects of analgesic use. 
Five hundred, eleven patients with histologically con- 
firmed colorectal cancer (346 colon patients, 165 rectum 
patients) were interviewed between 1989 and 1992 in 
five hospitals by trained personnel using a standardized 
questionnaire. Control subjects included 500 patients 
who were matched to each case patient by sex, race, 
hospital, age (+5 years), and month of interview. Eligi- 
ble control subjects included patients with conditions 
unrelated to NSAID use. Excluded specifically as admit- 
ting diagnoses were heart attacks, arthritis, and head- 
aches. The major control diagnoses were cancer 
(1 8.7%), genitourinary condtions (12.4%), musculo- 
skeletal/skin disorders (ll.loh), injuries (10.2%), 
slipped disks (8.9%), and benign prostatic hyperplasia 
(8.lY0). Informed consent was obtained from all sub- 
jects. Information was collected on sociodemographic 
variables, medical history, family history of cancer, 
pregnancy history, lifetime physical activity, smoking, 
and alcohol use. A food frequency section was used to 
obtain information on the major sources of total dietary 
fat and fiber. 
Subjects were asked the following questions: 
"Have you ever taken any over-the-counter pain reliev- 
ers?'' and "Have you ever taken any prescription pain 
relievers?" Information was recorded on the types and 
brand names of the pain relievers, the frequency and 
duration of use, the age of the patients when they first 
used the products, and the specific medical reasons 
given for taking the medications. The pathology reports 
of the case patients were examined to determine the site 
and stage of the tumor. Greater than 90% of the pa- 
tients who were approached participated, 
Nonsteroidal antiinflammatory drugs include aspi- 
rin, ibuprofen, indomethacin, and others. Acetamino- 
phens were defined as any pain relievers containing 
acetaminophen exclusively (e.g., regular and extra- 
strength Tylenol [McNeil Consumer Products, Ft. 
Washington, PA], aspirin-free Anacin [Whitehall Labo- 
ratories, New York, NY]). Most commercial brands con- 
tained 100% acetaminophen as the active ingredient. A 
few patients took products formulated with both acet- 
aminophen and aspirin. Regular use of NSAIDs and 
acetaminophen was defined as at  least 3 times per week 
for at least 1 year before the interview. This definition 
reduced the possible bias that could have resulted from 
patients taking pain relievers to treat the symptoms of 
their illness. Only one male case patient and one control 
subject took acetaminophen daily but discontinued use 
more than 1 year before the interview. Among the 
women, 1% of both case patients and control subjects 
took acetaminophen regularly but discontinued use 1 
year before the interview. 
The initial data analysis showed that the use of 
acetaminophen on a less-than-daily basis was not asso- 
ciated with the risk of colorectal cancer. We therefore 
present the risk estimates for daily acetaminophen use. 
Acetaminophen users were compared with patients 
who did not use both acetaminophen and NSAIDs. 
Matched-pair odds ratios (ORs) and 95% confidence in- 
tervals (CIS) were calculated by taking the ratio of dis- 
cordant case-control pairs.27 
Although the eligibility criteria for the hospital con- 
trols excluded such conditions as arthritis and head- 
aches, there may be other unknown medical conditions 
that are related to aspirin intake. Because it is important 
that the control group represent the population at risk, 
possible bias resulting from the selection of hospital 
subjects can be minimized by using control subjects 
with a variety of diagnoses.28 There were 180 distinct 
diagnoses among the control group. The control sub- 
jects were grouped according to major diagnostic cate- 
gories, and the prevalence of NSAID use was examined 
separately for each category. 
Results 
The basic characteristics of the case patients and control 
patients are shown in Table 2. Case patients and control 
subjects had similar ages, levels of education, and reli- 
gious affiliations. There was a slightly higher proportion 
of college graduates and Jewish males in the control 
group than in the case group. 
Thirty-eight percent of the case subjects and 47% 
of the control subjects took NSAIDs for at least 1 year 
(Table 2). Fifteen percent of male case patients used 
NSAIDs regularly (e.g., at least 3 times a week for at 
least 1 year) compared with 20% of control subjects. In 
addition, a greater percentage of male control subjects 
took NSAIDs 1-2 times per week for 9 or more years, 
as compared with male case patients (4.3% vs. 1.8%). 
Aspirin was the most common type of NSAID taken. 
Among women, 7.5% of case patients and 19.6% of 
control subjects took NSAIDs regularly. NSAIDs were 
taken regularly for as long as 40 years by some men and 
women. 
Forty-four percent of males and 62% of females 
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Table 2. Characteristics of 511 Colorectal Cases and 500 Controls 
Males Females 
Cases Controls Cases Controls 
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Values are no. (with percentages in parentheses). 
* At least 3 times per week for 1 or more years. 
t For 1 or more years. 
f Dailv use for 1 or more years. 
had ever taken acetaminophen. Only 3% of male case 
patients and 3% of male control subjects took acetamin- 
ophen daily for 1 year or more, compared with 6% of 
female case patients and 11% of female control sub- 
jects, respectively. Most of the acetaminophen taken by 
the patients was over-the-counter medication. In con- 
trast to the use of aspirin, no male patients had taken 
acetaminophen regularly for more than 9 years. 
The proportions of regular NSAID users (2 3 times 
per week for 1 or more years) in the control subgroups 
were: 12% of 92 control subjects with cancer or benign 
tumors (breast, prostate, melanoma, uterus, others); 
25% of 79 control subjects with skin or musculoskeletal 
conditions; 21% of 61 control subjects with genitouri- 
nary conditions; 20% of 50 control subjects with inju- 
ries; 36% of 44 control subjects with slipped disks; 17% 
of 41 control subjects with digestive conditions (mostly 
hernia and peritonitis); 19% of 31 control subjects with 
neurologic conditions; and 10% of 39 male case patients 
with benign prostatic hyperplasia. There were little pro- 
portional differences in NSAID use between men and 
women in each of these categories. 
The ORs for regular NSAID and acetaminophen 
use are shown in Table 3. The ORs for men who took 
NSAIDs regularly were 0.77 (95% CI, 0.34-1.75) for 1- 
4 years of use, 0.93 (95% CI, 0.45-1.97) for 5-9 years of 
use, and 0.47 (95% CI, 0.21-0.94) for more than 9 years 
of use. The OR for men who took NSAIDs 1-2 times 
per week for 9 or more years was 0.42 (95% CI, 0.15- 
1.15). Among women who took NSAIDs regularly, 
there was a significant decrease in risk for 1-4 years of 
use (OR = 0.17; 95% CI, 0.06-0.49), and for 5-9 years 
of use (OR = 0.13; 95% CI, 0.02-1.39). The relative risk 
for more than 9 years of regular NSAID use was 0.60 
(95% CI, 0.26-1.36). Overall, regular NSAID use was 
associated with a significant risk reduction in both men 
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Table 3. Matched-Pair Odds Ratio of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Acetaminophen Use in 
Relation to Colorectal Cancer 
Males Females 
Ratio OR 95% CI Ratio OR 95% CI 
Regular NSAIDs* 
1-4 10/13 0.77 0.34-1.75 3/18 0.17 0.06-0.49 
5-9 yr 13/14 0.93 0.45-1.97 1/8 0.13 0.02-1.39 
> 9 yr 8/17 0.47 0.21-0.94 9/15 0.60 0.26-1.36 
(1-2 times/wk for > 9 yr) 5/12 0.42 0.15-1.15 
Total 36/56 0.64 0.42-0.97 13/41 0.32 0.18-0.5 7 
Reasons for NSAID usaget 
Prevention 21/32 0.66 0.38-1.13 3/7 0.43 0.12-1.59 
Arthritis 6 / 6  1.00 - 3/23 0.13 0.05-0.36 
Headache/o thee 9/18 0.50 0.23-1.09 7/11 0.64 0.25-1.62 
Acetaminophen5 2 1 yr 7/6 1.07 0.35-3.23 17/12 0.59 0.27-1.25 
Values are cases and controls who took acetaminophen only and excludes compound products. The referent group includes subjects who took neither acetaminophen 
and NSAIDs. OR odds ratio; CI: confidence interval. 
* z 3 times per week. 
t Includes regular NSAID users and men who used NSAIDs for 1-2 times per week for > 9 years. 
$ Includes 5 male subjects and 4 female subjects who reported taking NSAlDs for treating trauma pain. 
tj Daily use, unmatched ORs. 
and women. No relationship with colorectal cancer was 
observed in women who used NSAIDs less than three 
times per week. There were little differences in risk 
when comparing the effects of NSAIDs between the 
left-sided colon and the right-sided colon. 
Women took NSAIDs on a regular basis primarily 
to treat arthritis and headaches, whereas the majority 
of men stated that they took NSAIDs to prevent heart 
disease. When the risk of colorectal cancer according to 
the reason given for taking NSAIDs (Table 3) was ex- 
amined, a decreased risk was found for men and 
women who took NSAIDs to prevent heart disease 
(men: OR = 0.66; 95% CI, 0.38-1.13; women: OR = 
0.43; 95% CI, 0.12-1.59) and for treating headache or 
other pain (men: OR = 0.5; 95% CI, 0.23-1.09; women: 
OR = 0.64; 95% CI, 0.25-1.62). A decreased risk also 
was found for women, but not for men, who took 
NSAIDs to treat arthritis (women: OR = 0.13; 95% CI, 
0.05-0.36; men: OR = 1.0). 
Information on tumor size was routinely available 
from four of the five participating hospitals, Of 356 case 
patients (70%), no significant differences in stage were 
found between NSAID users and other case patients. 
Of 50 case patients with Stage 1 tumors, only 6% were 
NSAID users, compared with 13% of case patients with 
larger tumor diameters. 
The ORs for daily acetaminophen use among sub- 
jects who did not take NSAIDs were 1.07 (95% CI, 
0.35-3.23) for men and 0.59 (95% CI, 0.27-1.25) for 
women (Table 3). When stratifying by years of daily 
acetaminophen intake, there was little heterogeneity in 
risk. Acetaminophen was taken by both men and 
women primarily to treat arthritis and headache pain. 
The association of large bowel cancer with other 
suspected risk factors was evaluated to determine pos- 
sible confounding in the data. No association was ob- 
served with body mass index and dietary intake of red 
meat, cheese, fruits, and vegetables. There was no asso- 
ciation with levels of physical activity, cigarette smok- 
ing, alcohol consumption, and coffee consumption. 
Family history of colorectal cancer was related signifi- 
cantly to the risk of colorectal cancer (OR = 2.8; 95% 
CI, 1.8-4.2) but unrelated to pain reliever use. A greater 
proportion of female control subjects had a history of 
rheumatoid arthritis, as compared with case patients 
(8.4% vs. 3.1), although the proportion of NSAID users 
was the same in both rheumatoid arthritis groups.29 
Discussion 
Our data are consistent with most previous epidemio- 
logic studies that found a reduced risk of colon cancer 
or colorectal cancer among regular users of aspirin or 
NSAIDS.'~-~~ We found little differences in the odds ra- 
tios when comparing the risk between left-sided and 
right-sided colon cancers, or between cancers of the co- 
lon and rectum. 
While our results support the hypothesis that regu- 
lar NSAID intake reduces the risk of large bowel cancer, 
the evidence that the protective effect increases with the 
duration of use has not been established. Some of the 
epidemiologic studies of NSAID use did not examine 
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the risk by the duration of NSAID intake. In studies 
conducted by Rosenberg et and Thun et al.,’l non- 
significant trends were found with increasing duration 
of NSAID use. In our study, the risk reduction among 
men increased with long term NSAID use (> 9 years). 
However, we found a greater protective effect among 
women who took NSAIDs for 1-9 years compared with 
women who used them for more than 9 years. Our data 
show that, at least for men, the reduction in risk in- 
creases with the duration of NSAID use. 
The relatively large risk reduction among women 
who used NSAIDs regularly for up to 9 years was at- 
tributable to the low prevalence of NSAID use among 
female case patients. Only 3 of 228 female case patients 
took NSAIDs regularly for 1-4 years, and 1 female case 
patient took NSAIDs for 5-9 years. The low prevalence 
of regular NSAID use in female cases (7%) may reflect 
a sampling bias. Twenty-one percent of 102 female case 
patients in the study conducted by Paganini-Hill et al.z3 
used aspirin regularly. The proportion of daily aspirin 
users in the American Cancer Society cohort20,z1 (9% of 
257 female case patients) was similar to our findings, 
although these study subjects were, on average, youn- 
ger than those in our study (57 years vs. 64 years). To 
help interpret the results from these and other epidemi- 
ologic studies of NSAID use, population-based data of 
aspirin intake should be gathered to determine the ex- 
tent to which these various study findings can be gen- 
eralized. The possibility of selection bias in our study 
also may be reflected in the ratio of colon to rectal can- 
cers. This ratio was 2:l in our study, compared with 
1:519 and 1:4,” respectively, in two other case-control 
studies of NSAID use. 
One possible reason why a significant trend with 
duration of NSAID intake may be difficult to detect in 
epidemiologic studies is that NSAIDs taken regularly at 
younger ages and before the formation of neoplastic 
polyps or de novo cancers arising from flat mucosa may 
not reduce the risk of colorectal cancer. Most clinical 
trials of aspirin-like compounds have been conducted 
with patients who have existing colonic lesions. For ex- 
ample, case reports and clinical trials with a small num- 
ber of patients have demonstrated that sulindac, a 
NSAID, reduces the size and number of polyps in pa- 
tients with familial polyposis when administered 
d a i l ~ . ~ O - ~ ~  A clinical trial of 793 patients with adenomas 
showed that regular aspirin users had a lower risk of 
new adenomas after a 1-year follow-up.z6 However, 
one recent study did show that aspirin use for 5 years or 
longer inhibited the formation of adenomatous pol- 
y p ~ . ~ ~  This association should be examined in other 
populations. Because the mechanisms by which 
NSAIDs potentially inhibit adenomas or colon tumor 
growth is unclear, the question on duration of use re- 
quires further study. 
Another important consideration in studies of aspi- 
rin and colorectal cancer is whether the observed asso- 
ciation is due to uncontrolled confounding. For exam- 
ple, persons taking NSAIDs to prevent heart disease 
may have different dietary and lifestyle habits than per- 
sons who take NSAIDs to treat pain. Our findings do 
not support this hypothesis, because a risk reduction 
was found for women who took NSAIDs for preventive 
purposes and for treating arthritic and headache pain. 
Similarly, men who used NSAIDs regularly for preven- 
tive purposes or the treatment of headache pain had a 
reduced risk of colorectal cancer. Most of these findings 
were not statistically sigruficant because there was 
lower statistical power to detect associations in sub- 
group analysis. Our findings should be supplemented 
with population-based data that determine the reasons 
why people use NSAIDs and whether NSAID users 
differ from nonusers with respect to diet, smoking and 
alcohol intake, regularity of physician visits, allergic re- 
action to aspirin, medical history, and various lifestyle 
habits. 
A common concern in studies of NSAIDs and colo- 
rectal cancer mortality is whether aspirin use induces 
gastrointestinal bleeding and, as a consequence, would 
lead to a detection bias. Such a bias would reduce the 
magnitude of any association between NSAID use and 
colorectal cancer. We observed no statistical differences 
between NSAID use and stage of disease. In fact, 
NSAID users were somewhat less likely to have been 
diagnosed with early stage tumors. 
Our hospital controls were selected on the basis of 
diseases or conditions that were considered unrelated to 
aspirin use. Excluded diagnoses included cardiovascu- 
lar disease, arthritis, and headaches. There may be 
other types of diseases or conditions among the hospital 
control subjects that are related to aspirin use, although 
there is little information to determine this. It is ex- 
pected that the frequency and duration of aspirin use 
among hospital control subjects would vary, as it does 
in the general population. Two lines of evidence indi- 
cate, however, that the choice of hospital control sub- 
jects did not result in a spurious association between 
colorectal cancer and NSAID intake. First, 20% of both 
male and female control subjects were regular NSAID 
users. This percentage is similar to the user rate among 
the population-based control subjects of the Cancer 
Prevention Study 11.” Secondly, except for the patients 
with benign prostatic hyperplasia and female patients 
with cancer, the frequency of NSAID use was greater 
among all the control subgroups than cases. Still, the 
suitability of some controls, especially cancer controls 
in studies of NSAID use may be somewhat problematic. 
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However, Rosenberg et al.I9 found no differences in risk 
when comparing cases to either cancer control subjects 
or noncancer control subjects. This group previously 
found no effect of NSAID use on other cancers.34 A Fin- 
nish study of patients with rheumatoid arthritis found 
significantly reduced incidences of colon, rectum, and 
stomach cancers, but not of other cancers.35 
Control patients admitted for slipped disks used 
NSAIDs more often than other control subjects (36% 
vs. 19%). A slipped disk is an acute condition that was 
not related to chronic aspirin use in this study. Among 
these patients who regularly took NSAIDs, six of seven 
men (86%) and eight of nine women (89%) took 
NSAIDs to treat arthritis pain. These results suggest that 
in this study, arthritis may be a risk factor for a slipped 
disk. If the 44 controls who were diagnosed with 
slipped disk were eliminated from the analysis, how- 
ever, the NSAID exposure rate for the entire control se- 
ries would be reduced only from 20% to 19%. 
The association between acetaminophen intake 
and large bowel cancer is more difficult to assess than 
that for NSAIDs, because acetaminophen is used less 
frequently among middle-aged and older men in the 
general population (McNeil Consumer Product Com- 
pany, unpublished data, 1992). Some acetaminophen 
products are compounded with aspirin, and a few pa- 
tients took both aspirin and acetaminophen to treat a 
particular illness. In the American Cancer Society stud- 
ies,20,21 there was no decrease in colon cancer rates 
among users of acetaminophen, although there was in- 
sufficient information to assess the risk for frequent 
acetaminophen users. In our study, women who took 
acetaminophen daily had a lower but nonsignificant re- 
duced risk of colorectal cancer. There were not enough 
male patients who took acetaminophen regularly to 
evaluate this association adequately. These findings 
suggest that a possible protective mechanism for acet- 
aminophen cannot be ruled out at this time. Acetamin- 
ophen has been suggested to be a prostaglandin forma- 
tion inhibitor,17 and earlier studies of laboratory rats 
that were fed the carcinogen N-2-fluorenylacetamide 
showed that acetanilide, a parent compound of acet- 
aminophen, inhibited liver tumor formation and in- 
creased survival time.36v37 The association with acet- 
aminophen could be examined with greater statistical 
power in a population with a high prevalence of arthri- 
tis, such as older women. 
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